Omeros Corporation is a biopharmaceutical company committed to discovering, developing, and commercializing small-molecule and protein therapeutics for large-market as well as orphan indications targeting inflammation, coagulopathies, and disorders of the central nervous system.

Omeros has clinical-stage development programs focused on complement-associated thrombotic microangiopathies; complement-mediated glomerulonephropathies; Huntington's disease and cognitive impairment; and addictive and compulsive disorders. In addition, Omeros has a diverse group of preclinical programs and two additional platforms: one capable of unlocking new G protein-coupled receptor, or GPCR, drug targets and the other used to generate antibodies.

The Company's marketed drug product OMIDRIA® was launched in the U.S. for use during cataract surgery or intraocular lens, or IOL, replacement. OMIDRIA is the first FDA-approved drug for use during cataract surgery or intraocular lens replacement to maintain pupil size by preventing intraoperative miosis and to reduce postoperative ocular pain and that contains a NSAID for intraocular use.

Omeros Corporation was founded in 1994 and is headquartered in Seattle, US

Chairman and Chief Executive Officer

Director

Vice President, Business Development

Omeros Corporation has an office in Seattle

Seattle, US (HQ)

201 Elliott Ave

Omeros Corporation's revenue was reported to be $12.3 m in Q1, 2017

USD

## Revenue (Q1, 2017) | 12.3 m |

## Gross profit (Q1, 2017) | 12 m |

## Gross profit margin (Q1, 2017), % | 98% |

## Net income (Q1, 2017) | (15.1 m) |

## EBIT (Q1, 2017) | (12.7 m) |

## Market capitalization (17-Aug-2017) | 990 m |

## Cash (31-Mar-2017) | 1.3 m |

Omeros Corporation's current market capitalization is $990 m.

USD | FY, 2013^{} | FY, 2014^{} | FY, 2015^{} | FY, 2016^{} |
---|---|---|---|---|

## Revenue | 1.6 m | 539 k | 13.5 m | 41.6 m |

## Revenue growth, % | (66%) | 2406% | 208% | |

## Cost of goods sold | 1 m | 1.4 m | ||

## Gross profit | 12.5 m | 40.2 m | ||

## Gross profit Margin, % | 92% | 97% | ||

## Operating expense total | 52.1 m | 70.5 m | 84.7 m | 95.9 m |

## EBIT | (50.5 m) | (70 m) | (71.2 m) | (54.3 m) |

## EBIT margin, % | (3157%) | (12988%) | (527%) | (130%) |

## Interest expense | (2.4 m) | (3.5 m) | (3.6 m) | (7.8 m) |

## Net Income | (39.8 m) | (73.7 m) | (75.1 m) | (66.7 m) |

USD | Q2, 2014^{} | Q3, 2014^{} | Q1, 2015^{} | Q2, 2015^{} | Q3, 2015^{} | Q1, 2016^{} | Q2, 2016^{} | Q3, 2016^{} | Q1, 2017^{} |
---|---|---|---|---|---|---|---|---|---|

## Revenue | 45 k | 214 k | 388 k | 3.2 m | 3.3 m | 7.4 m | 10 m | 11.3 m | 12.3 m |

## Cost of goods sold | 11 k | 365 k | 248 k | 327 k | 327 k | 378 k | 271 k | ||

## Gross profit | 377 k | 2.8 m | 3 m | 7.1 m | 9.7 m | 10.9 m | 12 m | ||

## Gross profit Margin, % | 97% | 89% | 92% | 96% | 97% | 97% | 98% | ||

## R&D expense | 12.4 m | 11.8 m | 9.3 m | 10.9 m | 13.3 m | 15.4 m | 10.2 m | 12.5 m | 12.2 m |

## General and administrative expense | 4.9 m | 5.6 m | 9 m | 7.9 m | 9 m | 11.1 m | 10.4 m | 10.5 m | 12.5 m |

## Operating expense total | 17.3 m | 17.3 m | 18.3 m | 18.8 m | 22.3 m | 26.5 m | 20.6 m | 22.9 m | 24.7 m |

## EBIT | (17.2 m) | (17.1 m) | (17.9 m) | (16 m) | (19.3 m) | (19.5 m) | (10.9 m) | (12 m) | (12.7 m) |

## EBIT margin, % | (38260%) | (8006%) | (4621%) | (501%) | (592%) | (262%) | (109%) | (107%) | (104%) |

## Interest expense | (939 k) | (944 k) | (957 k) | (937 k) | (871 k) | (1.4 m) | (1.9 m) | (2.1 m) | (2.7 m) |

## Net Income | (34.6 m) | (53 m) | (18.7 m) | (35.3 m) | (55.3 m) | (20.5 m) | (33.2 m) | (47.1 m) | (15.1 m) |

USD | FY, 2013^{} | FY, 2014^{} | FY, 2015^{} | FY, 2016^{} |
---|---|---|---|---|

## Cash | 1.4 m | 354 k | 1.4 m | 2.2 m |

## Accounts Receivable | 14.6 m | |||

## Inventories | 337 k | 472 k | 1.1 m | |

## Current Assets | 14.8 m | 9.2 m | 37.1 m | 60.3 m |

## PP&E | 939 k | 782 k | 951 k | 1.2 m |

## Total Assets | 16.5 m | 11.1 m | 49 m | 67.3 m |

## Accounts Payable | 2.3 m | 4.9 m | 6.4 m | 2.5 m |

## Current Liabilities | 11.9 m | 18.4 m | 16.3 m | 16.1 m |

## Additional Paid-in Capital | 235.7 m | 285.1 m | 376.5 m | 432 m |

## Retained Earnings | (254.4 m) | (328 m) | (403.1 m) | (469.9 m) |

USD | Q2, 2014^{} | Q3, 2014^{} | Q1, 2015^{} | Q2, 2015^{} | Q3, 2015^{} | Q1, 2016^{} | Q2, 2016^{} | Q3, 2016^{} | Q1, 2017^{} |
---|---|---|---|---|---|---|---|---|---|

## Cash | 1.5 m | 750 k | 1.4 m | 2.6 m | 601 k | 978 k | 4.6 m | 10.3 m | 1.3 m |

## Inventories | 566 k | 633 k | 445 k | 2 m | 1.8 m | 1.4 m | 960 k | ||

## Current Assets | 39 m | 23.4 m | 73.1 m | 56.7 m | 39.5 m | 24.3 m | 34.1 m | 60.6 m | 51.4 m |

## PP&E | 907 k | 846 k | 727 k | 789 k | 808 k | 898 k | 1.3 m | 1.2 m | 1.2 m |

## Total Assets | 41 m | 25.3 m | 74.9 m | 58.6 m | 41.4 m | 36 m | 46.1 m | 72.8 m | 58.4 m |

## Accounts Payable | 5.1 m | 4.2 m | 4.6 m | 4 m | 4.6 m | 5.3 m | 5.4 m | 4 m | 2.4 m |

## Current Liabilities | 12.2 m | 14.4 m | 20.1 m | 20.1 m | 22.3 m | 17.5 m | 16.1 m | 16.1 m | 17 m |

## Additional Paid-in Capital | 278.1 m | 280.4 m | 368.2 m | 370.9 m | 373.9 m | 382.5 m | 386.9 m | 427.1 m | 436.4 m |

## Retained Earnings | (289 m) | (307.3 m) | (346.7 m) | (363.4 m) | (383.3 m) | (423.7 m) | (436.3 m) | (450.3 m) | (485 m) |

## Total Equity | 7.9 m | (9 m) | |||||||

## Financial Leverage | 7.4 x | -4.6 x |

USD | FY, 2013^{} | FY, 2014^{} | FY, 2015^{} | FY, 2016^{} |
---|---|---|---|---|

## Net Income | (39.8 m) | (73.7 m) | (75.1 m) | (66.7 m) |

## Depreciation and Amortization | 302 k | 326 k | 209 k | 300 k |

## Inventories | 96 k | (656 k) | ||

## Accounts Payable | 4.2 m | (319 k) | ||

## Cash From Operating Activities | (29.7 m) | (58 m) | (65.2 m) | (51.5 m) |

## Purchases of PP&E | (204 k) | |||

## Cash From Investing Activities | 7.9 m | 6.2 m | (20.6 m) | (16.3 m) |

## Long-term Borrowings | (1.5 m) | |||

## Cash From Financing Activities | 21.7 m | 50.9 m | 86.8 m | 68.7 m |

## Interest Paid | 1.7 m | 2.7 m | 4.2 m | 5.3 m |

USD | Q2, 2014^{} | Q3, 2014^{} | Q1, 2015^{} | Q2, 2015^{} | Q3, 2015^{} | Q1, 2016^{} | Q2, 2016^{} | Q3, 2016^{} | Q1, 2017^{} |
---|---|---|---|---|---|---|---|---|---|

## Net Income | (34.6 m) | (53 m) | (18.7 m) | (35.3 m) | (55.3 m) | (20.5 m) | (33.2 m) | (47.1 m) | (15.1 m) |

## Depreciation and Amortization | 164 k | 246 k | 55 k | 107 k | 161 k | 53 k | 122 k | 211 k | |

## Inventories | (1.5 m) | (1.3 m) | (924 k) | 960 k | |||||

## Accounts Payable | 4.3 m | 3.9 m | 1.3 m | (268 k) | (303 k) | 2.4 m | |||

## Cash From Operating Activities | (26.4 m) | (42.4 m) | (17.5 m) | (34 m) | (48.6 m) | (16.6 m) | (29.4 m) | (40.6 m) | |

## Cash From Investing Activities | (23.2 m) | (8.3 m) | (62.1 m) | (42.5 m) | (28.1 m) | 14.6 m | 10.2 m | (10.3 m) | |

## Short-term Borrowings | (4.7 m) | ||||||||

## Long-term Borrowings | (1.5 m) | (1.5 m) | (2.3 m) | (34 k) | (62 k) | ||||

## Cash From Financing Activities | 49.8 m | 50 m | 80.7 m | 78.7 m | 76.9 m | 1.6 m | 22.4 m | 59.9 m | |

## Interest Paid | 1.2 m | 1.9 m | 745 k | 1.5 m | 2.1 m | 776 k | 2 m | 3.6 m |

USD | Y, 2017 |
---|---|

## Revenue/Employee | 75.7 k |